Imfinzi-Imjudo dual immunotherapy offers new option for 1st-line treatment of liver cancer < Pharma < Article
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have...
Immunotherapy
Adding Immunotherapy to Local Treatment Delays Liver Cancer Progression
Adding the immune checkpoint inhibitor Imfinzi (durvalumab) and the VEGF inhibitor Avastin (bevacizumab) to transarterial chemoembolization (TACE) led to improved...
